Jose C. Tapia

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

A Survey of Oncologists' Perceptions and Opinions Regarding Brain Imaging in Metastatic Renal Cell Carcinoma Within the UK.

A Survey of Oncologists' Perceptions and Opinions Regarding Brain Imaging in Metastatic Renal Cell Carcinoma Within the UK.

Journal: Cureus

Published: February 12, 2026

Refining Prognosis in Advanced Renal Cell Carcinoma: International Real-World Validation of the Meet-URO Score in First-Line Immunotherapy Combinations.

Refining Prognosis in Advanced Renal Cell Carcinoma: International Real-World Validation of the Meet-URO Score in First-Line Immunotherapy Combinations.

Journal: The oncologist

Published: December 16, 2025

Refining prognosis in advanced renal cell carcinoma: international real-world validation of the Meet-URO score in first-line immunotherapy combinations.

Refining prognosis in advanced renal cell carcinoma: international real-world validation of the Meet-URO score in first-line immunotherapy combinations.

Journal: The oncologist

Published: December 16, 2025

Real-World Outcomes of First-Line Ipilimumab Plus Nivolumab in Advanced Renal Cell Carcinoma: A UK Multi-Centre Retrospective Study.

Real-World Outcomes of First-Line Ipilimumab Plus Nivolumab in Advanced Renal Cell Carcinoma: A UK Multi-Centre Retrospective Study.

Journal: Clinical genitourinary cancer

Published: November 03, 2025

International analysis of reimbursement rates and clinical benefit of genitourinary cancer drugs across Canada, France, England, Wales, Scotland, Spain, Italy, and Portugal.

International analysis of reimbursement rates and clinical benefit of genitourinary cancer drugs across Canada, France, England, Wales, Scotland, Spain, Italy, and Portugal.

Journal: International journal of cancer

Published: August 29, 2025

Prognostic immunotherapy score (PIS) in patients with advanced urothelial carcinoma treated with pembrolizumab: real-world data and validation from ARON-2 dataset.

Prognostic immunotherapy score (PIS) in patients with advanced urothelial carcinoma treated with pembrolizumab: real-world data and validation from ARON-2 dataset.

Journal: Clinical & experimental metastasis

Published: March 11, 2025

Activity of lenvatinib-based therapy in previously treated patients with metastatic renal cell carcinoma: A European multicenter study (LENVA-LAT).

Activity of lenvatinib-based therapy in previously treated patients with metastatic renal cell carcinoma: A European multicenter study (LENVA-LAT).

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 29, 2025

Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab.

Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab.

Journal: Scientific reports

Published: July 22, 2024

The FLARE Score and Circulating Neutrophils in Patients with Cancer and COVID-19 Disease.

The FLARE Score and Circulating Neutrophils in Patients with Cancer and COVID-19 Disease.

Journal: Cancers

Published: July 12, 2024

What About Variant Histologies in Bladder Cancer?

What About Variant Histologies in Bladder Cancer?

Journal: European urology focus

Published: February 21, 2024

Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study.

Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study.

Journal: Scientific reports

Published: February 18, 2024

Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.

Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.

Journal: Cancer immunology, immunotherapy : CII

Published: February 05, 2024

Showing 1-12 of 28

Last Updated: 09/26/2026